Tetraphase Pharmaceuticals to Present Data at IDWeek 2017
September 25, 2017 09:05 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections
September 11, 2017 07:00 ET
|
Tetraphase Pharmaceuticals
- Top-line Data Expected in 1Q 2018 - - IGNITE3 Results to Support U.S. sNDA Filing for IV Eravacycline in cUTI – WATERTOWN, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals,...
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
August 17, 2017 08:30 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements
August 02, 2017 16:14 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Announces Pricing of Public Offering of Common Stock
July 27, 2017 20:21 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Announces Proposed Public Offering of Common Stock
July 26, 2017 16:30 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
July 25, 2017 16:01 ET
|
Tetraphase Pharmaceuticals
̶ IV Eravacycline Achieves Primary Endpoint in Second of Two Pivotal Trials in cIAI ̶ ̶ Company Proceeding with Regulatory Submissions in Europe in 3Q 2017 and U.S. in 1Q 2018 ̶ ̶ Ongoing...
Tetraphase Pharmaceuticals Announces Positive Phase 1 Single-Ascending Dose Data for Antibiotic Pipeline Candidates
June 05, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...
Tetraphase Pharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 08:00 ET
|
Tetraphase Pharmaceuticals
WATERTOWN, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening...